Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer

키워드

참고문헌 (43)

1. Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)[DOI]
2. Doubeni CA, "Diagnosis and management of ovarian cancer", Am Fam Physician, 93, pp.937~944 (2016)
3. "Surveillance, Epidemiology, and End Results program. Statistical summaries: cancer stat fact sheets (ovary) and cancer statistics review (CSR), 1975-2013"[URL]
4. Surveillance, Epidemiology, and End Results (SEER) program. SEER*Stat Database: NAACCR Incidence Data - CiNA Analytic File -, for Expanded Races, Custom File With County, ACS Facts and Figures projection Project (which includes data from CDC's National Program of Cancer Registries (NPCR), CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results (SEER) Registries), certified by the North American Association of Central Cancer Registries (NAACCR) as meeting high-quality incidence data standards for the specified time periods, submitted December 2016, "National Cancer Institute", National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch, ~ (2016)
5. Rojas V, "Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment", Int J Mol Sci, 17, pp.E2113~ (2016)[DOI]
6. Barbieri F, "Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target", J Oncol, 2010, pp.426956~ (2010)
7. Kurman RJ, "The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded", Am J Pathol, 186, pp.733~747 (2016)[DOI]
8. Hall J, "Critical evaluation of p53 as a prognostic marker in ovarian cancer", Expert Rev Mol Med, 6, pp.1~20 (2004)
9. Cancer Genome Atlas Research Network, "Integrated genomic analyses of ovarian carcinoma", Nature, 474, pp.609~615 (2011)[DOI]
10. Shih IM, "Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis", Am J Pathol, 164, pp.1511~1518 (2004)[DOI]
11. Chan WY, "Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers", Am J Pathol, 156, pp.409~417 (2000)[DOI]
12. Pils D, "In ovarian cancer the prognostic influence of HER2", neu is not dependent on the CXCR4, Br J Cancer, pp.2007, 96[DOI]
13. Popple A, "The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer", Br J Cancer, 106, pp.1306~1313 (2012)[DOI]
14. Haghnegahdar H, "The tumorigenic and angiogenic effects of MGSA", GRO proteins in melanoma, 2000, pp.67, 53~62
15. Rubie C, "ELR+ CXC chemokine expression in benign and malignant colorectal conditions", BMC Cancer, 8, pp.178~ (2008)[DOI]
16. Palacios-Arreola MI, "The role of chemokines in breast cancer pathology and its possible use as therapeutic targets", J Immunol Res, 2014, pp.849720~ (2014)
17. Di Minin G, "Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP", Mol Cell, 56, pp.617~629 (2014)[DOI]
18. Son DS, "Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of <TEX>$I{\kappa}B$<", TEX>, 2012, pp.7, e51116~
19. Hacke K, "Regulation of MCP-1 chemokine transcription by p53", Mol Cancer, 9, pp.82~ (2010)[DOI]
20. Perez-Llamas C, "Gitools: analysis and visualisation of genomic data using interactive heat-maps", PLoS One, 6, pp.e19541~ (2011)[DOI]
21. Gyorffy B, "Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients", Endocr Relat Cancer, 19, pp.197~208 (2012)[DOI]
22. Cerami E, "The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)[DOI]
23. Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6 (2013)
24. Vang R, "Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas ovarian study", Int J Gynecol Pathol, 35, pp.48~55 (2016)[DOI]
25. Ness RB, "Possible role of ovarian epithelial inflammation in ovarian cancer", J Natl Cancer Inst, 91, pp.1459~1467 (1999)[DOI]
26. Ignacio RM, "<TEX>$NF-{\kappa}B$<", TEX>-mediated CCL20 reigns dominantly in CXCR2-driven ovarian cancer progression, 2016, pp.11, e0164189~
27. Yuan L, "Evaluation of serum CCL18 as a potential biomarker for ovarian cancer", Cancer Biomark, 21, pp.97~104 (2017)[DOI]
28. Gu XL, "Expression of CXCL14 and its anticancer role in breast cancer", Breast Cancer Res Treat, 135, pp.725~735 (2012)[DOI]
29. Tessema M, "Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis", Oncogene, 29, pp.5159~5170 (2010)[DOI]
30. Shellenberger TD, "BRAK", CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells, 2004, pp.64, 8262~8270
31. Hromas R, "Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells", Biochem Biophys Res Commun, 255, pp.703~706 (1999)[DOI]
32. Sjoberg E, "Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer", Br J Cancer, 114, pp.1117~1124 (2016)[DOI]
33. Belperio JA, "CXC chemokines in angiogenesis", J Leukoc Biol, 68, pp.1~8 (2000)
34. Liu M, "The emerging role of CXCL10 in cancer (Review)", Oncol Lett, 2, pp.583~589 (2011)[DOI]
35. Monteagudo C, "CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors", J Clin Pathol, 60, pp.596~599 (2007)[DOI]
36. Furuya M, "Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis", Hum Pathol, 38, pp.1676~1687 (2007)[DOI]
37. Yeudall WA, "Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration", Carcinogenesis, 33, pp.442~451 (2012)[DOI]
38. An H, "CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma", Eur J Cancer, 51, pp.1953~1961 (2015)[DOI]
39. Qiao B, "The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis", Oncotarget, 9, pp.15068~15076 (2017)
40. Yang G, "CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis", Clin Cancer Res, 16, pp.3875~3886 (2010)[DOI]
41. Nesbeth Y, "CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion", Cancer Res, 69, pp.6331~6338 (2009)[DOI]
42. Wong JL, "IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment", Cancer Res, 73, pp.4653~4662 (2013)[DOI]
43. Muralidhar GG, "Chemokine receptors in epithelial ovarian cancer", Int J Mol Sci, 15, pp.361~376 (2013)[DOI]

관련 논문AI추천